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Clinically isolated syndrome (CIS) suggestive of multiple scle-
rosis (MS) is the first clinical episode in patients who will po-
tentially develop MS. To determine whether early treatment
following a CIS, can delay the second clinical event and a dia-
gnosis of clinically definite MS (CDMS), five placebo-control-
led clinical trials with conventional disease modifying therapies
(DMT) were conducted..
In the CHAMPS (Controlled High-Risk Subjects AVONEX
Multiple Sclerosis Prevention Study) study, weekly injections
of 30 mcg interferon (IFN)-beta 1a im resulted in a significant
reduction of the cumulative probability of the development of
CDMS (35% vs. 50% for placebo; p=0.002). In the ETOMS
(Early Treatment Of Multiple Sclerosis) trial, the rate of con-
version to CDMS was reduced from 45% to 34% (p=0.047)
for once-weekly treatment with 22 mcg IFN-beta 1a sc. In the
BENEFIT (BETAFERON in Newly Emerging Multiple Scle-
rosis for Initial Treatment) study, treatment with IFN-beta 1b
250 mcg sc every other day delayed time to CDMS by 363 days
(HR: 0.50; p<0.0001) and decreased the risk for CDMS by
50%. In the PreCISe (early glatiramer acetate treatment in de-
laying conversion to clinically definite multiple sclerosis in sub-
jects Presenting with a Clinically Isolated Syndrome trial) gla-
tiramer acetate (GA) 20 mg/d reduced conversion to CDMS by
45% (p=0.0005) with the time to conversion significantly pro-
longed from 336 days to 722 days. Finally, recently, another
study with IFN-beta 1a sc was performed in CIS. In this Rebif
FLEXible dosing in early multiple sclerosis (REFLEX) study,
patients were randomly assigned to receive IFN-beta 1a sc 44
mcg three times a week, once weekly, or placebo. The two year
rate of conversion to CDMS was lower for both doses of IFN-
beta 1a  sc (three times a week 63%, p<0.0001; once weekly
76%, p=0.008) compared to placebo (86%). Thus, all these
trials with IFN-beta and GA have shown a consistent reduc-
tion in the cumulative probability of developing CDMS in CIS
patients receiving early treatment. Additionally, they demon-
strated that IFN-beta and GA decreased the number of lesions
detected on brain MRI. However, up to now extension studies
and follow up data, which demonstrated persisting benefits in
relapse activity, have not shown an effect in preventing early di-
sability. Therefore, having all above-mentioned in mind, along
with the poor adherence rates and side effects, DMT should be
offered to selected CIS patients at high risk of developing MS.
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